“Our intent is to give doctors and patients an adjunct to traditional antiemetics and help speed post operative recovery times and patient quality of life.” stated Pressure Point Chairman and CEO Joseph DiLustro.
Tinton Falls, NJ (PRWEB) February 16, 2015
Tinton Falls, NJ – Pressure Point Inc., the global provider of the Pressure Right acupressure anti-nausea wrist strips used by anesthesiologists as part of a multi-modal antiemetic strategy for thousands of patients for postoperative nausea and vomiting, announced today that effective immediately it will offer their SmartCare™ program to hospitals for nausea and vomiting management for multiple indications.
“Our company is taking the lead in management-free nausea and vomiting effectiveness by providing this innovative program.” stated Pressure Point Chairman and CEO Joseph DiLustro. “Our intent is to give doctors and patients an adjunct to traditional antiemetics and help speed post operative recovery times and patient quality of life.”
Pressure Right Strips received FDA 510(k) market clearance in 2011 as an (Rx) product for surgical procedures to prevent the effects of postoperative nausea and vomiting following surgery. Last year, Pressure Right was granted FDA clearance as an over the counter product for nausea relief for other indications, such as, chemotherapy, pregnancy morning sickness and travel/motion sickness.
The Pressure Right clinical trial concluded by Dr. White in 2010, entitled: Use of Disposable Acupressure Device as Part of a Multi-Modal Antiemetic Strategy for Reducing Postoperative Nausea and vomiting, was clinically assessed as an adjunct to antiemetic therapy. The clinical trial found the Pressure Right group’s PONV was substantially reduced with a quality of recovery improvement at 72-hours following surgery. Additionally, the usage in rescue medications in the Pressure Right group showed a marked reduction of 57% 0-24 h and 64% 0-72 h respectively, compared to the antiemetic group alone.
Also, the Pressure Right group achieved a patient satisfaction rating of 84% among highly satisfied patients with their PONV management. This compared to a 66% rating for the antiemetic group. Dr. White’s research results were peer-reviewed and published in the Anesthesia Journal in 2012.
In a recent editorial article published in the December 2014 issue of the European Journal of Anesthesiology (EJA), written by Peter Kranke, M.D. & MBA, entitled: 2014 Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: [He quotes the Lichtor and Glass’ editorial and accompanying research published in 2008 entitled: We’re tired of waiting for nausea and vomiting to end.]
Dr. Kranke also refers to the Habib & Gan’s editorial article published in 2012: PONV Then & Now. Here the authors reflect on the achievements in the management of PONV: 80% incidence in the ether and chloroform era to a 20%-30% incidence nowadays. [Dr. Kranke and his colleagues do not agree with the Habib & Gan article and believe the 20% to 30% cannot be the ultimate target.]
The Pressure Right SmartCare™ program can help improve overall comprehensive care with mainstream medical institutions who are looking to achieve progressive initiatives focused on preventing “prolonged” PONV and chemo-induced nausea and vomiting symptoms.
About Pressure Point Inc.
Pressure Point has been a hospital-based provider of Pressure Right Anti-Nausea Strips since 2012.
Pressure Right is now FDA cleared as an OTC consumer product for multiple anti-nausea indications. These include chemotherapy, pregnancy (morning sickness), surgery and travel/motion sickness.
Pressure Point Inc.